SPONTAN® Phase II data meets FDA Pre-IND requirements
May 05, 2026 | 10:45
Interim Phase II data for SPONTAN® demonstrate rapid onset and a favourable pharmacokinetic profile, addressing FDA Pre-IND requirements across adult and elderly populations.
Mobile Version